Information:
Fel:
ID
26084
Beskrivning
A Trial of Panobinostat and Trastuzumab for Adult Female Patients With HER2 Positive Metastatic Breast Cancer Whose Disease Has Progressed on or After Trastuzumab; ODM derived from: https://clinicaltrials.gov/show/NCT00567879
Länk
https://clinicaltrials.gov/show/NCT00567879
Nyckelord
Versioner (1)
- 2017-10-09 2017-10-09 -
Rättsinnehavare
See clinicaltrials.gov
Uppladdad den
9 oktober 2017
DOI
För en begäran logga in.
Licens
Creative Commons BY 4.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
Eligibility Breast Cancer NCT00567879
Eligibility Breast Cancer NCT00567879
- StudyEvent: Eligibility
Similar models
Eligibility Breast Cancer NCT00567879
- StudyEvent: Eligibility
Name
Typ
Description | Question | Decode (Coded Value)
Datatyp
Alias
Age
Item
age > 18 year old
boolean
C0001779 (UMLS CUI [1])
Secondary malignant neoplasm of female breast HER2/Neu Positive
Item
confirmed her2+ ve metastatic breast cancer
boolean
C0346993 (UMLS CUI [1,1])
C2348909 (UMLS CUI [1,2])
C2348909 (UMLS CUI [1,2])
Trastuzumab | Disease Progression
Item
prior treatment and progression on trastuzumab
boolean
C0728747 (UMLS CUI [1])
C0242656 (UMLS CUI [2])
C0242656 (UMLS CUI [2])
Normal Laboratory Test Result
Item
patients must have adequate laboratory values
boolean
C0438214 (UMLS CUI [1])
ECOG performance status
Item
eastern cooperative oncology group (ecog) performance status of <2
boolean
C1520224 (UMLS CUI [1])
CNS disorder | Metastatic malignant neoplasm to brain | Exception Prior Therapy | Exception Stable status
Item
patients with active central nervous system (cns) disease or brain metastases except those who have been previously treated and have been stable for at least 3 months.
boolean
C0007682 (UMLS CUI [1])
C0220650 (UMLS CUI [2])
C1705847 (UMLS CUI [3,1])
C1514463 (UMLS CUI [3,2])
C1705847 (UMLS CUI [4,1])
C0205360 (UMLS CUI [4,2])
C0220650 (UMLS CUI [2])
C1705847 (UMLS CUI [3,1])
C1514463 (UMLS CUI [3,2])
C1705847 (UMLS CUI [4,1])
C0205360 (UMLS CUI [4,2])
Cardiac function Impaired | Heart Disease
Item
impaired heart function or clinically significant heart disease
boolean
C0232164 (UMLS CUI [1,1])
C0221099 (UMLS CUI [1,2])
C0018799 (UMLS CUI [2])
C0221099 (UMLS CUI [1,2])
C0018799 (UMLS CUI [2])
Abnormal digestive tract function | Gastrointestinal Disease Changing Absorption LBH589
Item
impairment of gastrointestinal (gi) function, or gi disease that may significantly alter the absorption of lbh589
boolean
C0232459 (UMLS CUI [1])
C0017178 (UMLS CUI [2,1])
C0392747 (UMLS CUI [2,2])
C0237442 (UMLS CUI [2,3])
C1566164 (UMLS CUI [2,4])
C0017178 (UMLS CUI [2,1])
C0392747 (UMLS CUI [2,2])
C0237442 (UMLS CUI [2,3])
C1566164 (UMLS CUI [2,4])
Diarrhea
Item
ongoing diarrhea
boolean
C0011991 (UMLS CUI [1])
Liver disease | Kidney Disease | Liver Dysfunction | Renal Insufficiency
Item
liver or renal disease with impaired hepatic or renal functions
boolean
C0023895 (UMLS CUI [1])
C0022658 (UMLS CUI [2])
C0086565 (UMLS CUI [3])
C1565489 (UMLS CUI [4])
C0022658 (UMLS CUI [2])
C0086565 (UMLS CUI [3])
C1565489 (UMLS CUI [4])
Cancer treatment | Antineoplastic Agents
Item
concomitant use of any anti-cancer therapy or certain drugs
boolean
C0920425 (UMLS CUI [1])
C0003392 (UMLS CUI [2])
C0003392 (UMLS CUI [2])
Pregnancy | Breast Feeding
Item
female patients who are pregnant or breast feeding
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
C0006147 (UMLS CUI [2])
Contraceptive methods Unwilling
Item
patients not willing to use an effective method of birth control
boolean
C0700589 (UMLS CUI [1,1])
C0558080 (UMLS CUI [1,2])
C0558080 (UMLS CUI [1,2])
Clinical Trial Eligibility Criteria Study Protocol
Item
other protocol-defined inclusion/exclusion criteria may apply
boolean
C1516637 (UMLS CUI [1,1])
C2348563 (UMLS CUI [1,2])
C2348563 (UMLS CUI [1,2])